Tag:

Avastin

Latest Headlines

Latest Headlines

ASCO: Celldex's glioblastoma vaccine scores a clear survival benefit

Celldex has added another round of positive data demonstrating that its brain cancer vaccine rindopepimut--more formally called Rintega and less formally "rindo"--provided a clear though relatively modest average survival benefit for recurrent glioblastoma patients in a Phase II study. And with the initial data set from Phase III looming later in the year, the biotech is carefully moving forward with its ongoing dialogue with regulators to gauge just how receptive they may be to speeding up an approval.

Roche nabs EU approval for Avastin for cervical cancer

Roche's Avastin has been on the market for more than a decade and boasts a long list of valuable approvals. But Roche is not sitting back the status quo, and continues to submit the drug for new uses. Now, the company racked up yet another OK for Avastin, scoring European approval for the drug in combination with chemotherapy to treat women with advanced cervical cancer months after the company got a similar decision from stateside regulators.

BMJ: Novartis tried to 'scupper' trials to protect Lucentis from cheap Avastin

Did Novartis and Roche campaign against study data supporting cheap Avastin eye injections as a substitute for their own purpose-made vision drug Lucentis? The  BMJ  says they did, aiming to "undermine and divert attention" from trials pitting Lucentis against the much cheaper treatment. 

Genentech's top-billing Lucentis users are also top-paid speakers: NYT

How did Genentech persuade physicians to switch from $50-a-dose Avastin to $2000-a-dose Lucentis? According to The New York Times, consultation payments may have had something to do with it.

Doc coughs up $2M for using unapproved Avastin on his cancer patients

A U.S. oncologist who thought he was getting a great deal on drugs that were almost the same thing as Avastin has found they will cost him an extra $2 million and a federal misdemeanor conviction.

Roche's Avastin wins FDA green light in ovarian cancer

Roche's Avastin is now two-for-two on converting recent FDA priority review designations into label expansions. Just three months after the cancer giant nabbed the agency's blessing for use in cervical cancer, regulators have approved the drug in combination with chemotherapy as a treatment for platinum-resistant, recurrent ovarian cancer.

Turkish man sent to prison for smuggling fake Avastin into U.S.

A Turkish man who admitted to smuggling counterfeit cancer drugs to the U.S. labeled as gifts or documents has been sentenced to 27 months in federal prison.

More heat applied to Genentech CEO for supply-chain decision on cancer drugs

Genentech CEO Ian Clark is again being publicly chastised for his company's decision to move three of its best-selling cancer drugs to specialty distributors. Groups representing more than 5,000 hospitals say, besides higher costs, the move is as likely to encourage counterfeiting as to deter it.

Regeneron's Eylea bests Lucentis, Avastin in diabetic eye disease, NIH study finds

Regeneron and Bayer's Eylea has been racking up sales that have consistently topped analyst expectations since its U.S. rollout in late 2011. Now, new data may help it potentially top them in a market Novartis and Roche got to first.

Peg cancer drug prices to effectiveness, '60 Minutes' interviewee suggests

On  " 60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking--and politicians, too.